A Phase 2 interventional study of Experimental: LTG-001 High Dose and Experimental: LTG-001 Low Dose in Acute Pain and Postoperative Pain Control, sponsored by Latigo Biotherapeutics. Completed at 5 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by Latigo Biotherapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 351 studies in Acute Pain with a site in United States — 47 open to participants now, 53 under way, 1 of them phase 3. Acute Pain · United States.
Among the 351 studies in Acute Pain with a site in United States, this one is the 39th largest by enrollment of the 320 interventional ones that give a count, is one of 15 that started in 2025, is one of 54 in phase 2, and was the 334th registered.
1,075 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
Browse Acute Pain studies →47 of the 351 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
Aponia Laboratories, Inc. · Sites in United States, Germany
Ages 18–65
Florida State University · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States
Ages 18–40
Ochsner Health System · Sites in United States
Ages 35+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
351 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 63 · Phase 3 48 · Phase 4 66
First in 2001; this study’s year is marked. 15 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 343 is above the median of 86 across 903 interventional studies indexed under Acute Pain.
Median enrollment 84 across the 320 interventional studies, 100 across the 31 observational. Of the 265 that completed or were terminated, 132 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
78 of 351 have an industry lead sponsor. The 10 most frequent:
Latigo Biotherapeutics is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Latigo Biotherapeutics has 2 studies filed under Acute Pain — fewer than ten, so there is no comparison to draw.
31 of the studies in Acute Pain with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07930559Phase 3Aponia Laboratories, Inc.Effect of S-Ibuprofen Gel on Pain in Acute Soft Tissue Contusions | 2027-06 |
| NCT07511816Eli Lilly and CompanyA Study of LY4515100 in Participants With Pain Following Third Molar Removal | 2026-11 |
| NCT05335070Rutgers, The State University of New JerseyReducing Pain From Wisdom Molar Extractions | 2026-11 |
| NCT06795126Nationwide Children's HospitalLittle NIRVANA for Pediatric Pain and Anxiety | 2026-11-30 |
| NCT05458037Women and Infants Hospital of Rhode IslandRCT of Pain Perception With Fast and Slow Tenaculum Application | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 351 studies in Acute Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if LTG-001 works to treat post-operative / acute pain after an abdominoplasty procedure. It will also learn more information on the safety of LTG-001.
The main questions it aims to answer are:
Does drug LTG-001 treat the acute pain after surgical abdominoplasty over 48 hours? How tolerable is LTG-001 over 48 hours? What dose of LTG-001 is better for treating post-operative / acute pain?
Participants will:
Take LTG-001 bid after the surgical abdominoplasty. Remain at the clinic for approximately 48 hours during study dosing and return after two weeks for a safety check up. Report the pain relief during the 48 hours to record changes in the post-operative pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
High Dose LTG-001
Drug: Experimental: LTG-001 High Dose
Drug: Experimental: LTG-001 Low Dose
Drug: Active Comparator: HB/APAP
Drug: Placebo Comparator
High Dose Active
Lower Dose Active
Drug page: Acetaminophen
Active Comparator
Placebo
SPIDr0-48
Time-weighted SPIDr0-48 after the first dose of study drug.
Time frame: 48 hours
Total Opioid Rescue
Total opioid rescue medication consumption from 0 48 hours, using MMEs
Time frame: 48 hours
No Opioid requirement
Proportion of participants requiring no opioid rescue medication over 48 hours
Time frame: 48 hours
2-Point NPRS Reduction
Time to ≥2-point reduction in NPRS from baseline
Time frame: 48 hours
1-Point NPRS Reduction
Time to ≥1-point reduction in NPRS from baseline
Time frame: 48 Hours
Nausea and Vomiting
Incidence of nausea or vomiting
Time frame: 48 hours
PID at 60 minutes
Time-specific PID at 60 minutes
Time frame: 1 hour
SPID r0-24
Time-weighted SPIDr0-24 after the first dose of study drug
Time frame: 24 hours
Patient Global Assessment
Proportion of participants with favorable PGA of study drug at end of treatment
Time frame: 48 Hours
Plan to share: No
Ran from Jul 2025 to primary completion in Jan 2026, 5 months.
Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LTG-001
Latigo Biotherapeutics